Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BrECADD versus escalated BEACOPP for advanced classical Hodgkin lymphoma
ACTRN12617000087358Phase 3Completed
- Sponsor
- University of Cologne
- Start
- Apr 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin, cyclophosphamide, doxorubicin, etoposide, dacarbazine and 5 more in classical Hodgkin lymphoma (cHL) (3 arms), sponsored by University of Cologne. Primary endpoints: Progression-free survival, Serious treatment-related morbidity and 1 more. Started Apr 2018; status: completed.
02
Drugs
brentuximab vedotincyclophosphamidedoxorubicinetoposidedacarbazine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ACTRN12617000087358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000087358.